PNTG vs. LFST, PRVA, USPH, INNV, WGS, TALK, DCGO, SHCR, PIII, and EUDA
Should you be buying The Pennant Group stock or one of its competitors? The main competitors of The Pennant Group include LifeStance Health Group (LFST), Privia Health Group (PRVA), U.S. Physical Therapy (USPH), InnovAge (INNV), GeneDx (WGS), Talkspace (TALK), DocGo (DCGO), Sharecare (SHCR), P3 Health Partners (PIII), and EUDA Health (EUDA). These companies are all part of the "health services" industry.
The Pennant Group (NASDAQ:PNTG) and LifeStance Health Group (NASDAQ:LFST) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
The Pennant Group currently has a consensus target price of $24.00, indicating a potential upside of 1.95%. LifeStance Health Group has a consensus target price of $8.80, indicating a potential upside of 57.99%. Given LifeStance Health Group's higher probable upside, analysts plainly believe LifeStance Health Group is more favorable than The Pennant Group.
The Pennant Group has higher earnings, but lower revenue than LifeStance Health Group. LifeStance Health Group is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, The Pennant Group and The Pennant Group both had 5 articles in the media. The Pennant Group's average media sentiment score of 0.57 beat LifeStance Health Group's score of 0.55 indicating that The Pennant Group is being referred to more favorably in the media.
85.9% of The Pennant Group shares are owned by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are owned by institutional investors. 5.8% of The Pennant Group shares are owned by insiders. Comparatively, 6.6% of LifeStance Health Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
The Pennant Group received 24 more outperform votes than LifeStance Health Group when rated by MarketBeat users. Likewise, 44.74% of users gave The Pennant Group an outperform vote while only 26.32% of users gave LifeStance Health Group an outperform vote.
The Pennant Group has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
The Pennant Group has a net margin of 2.86% compared to LifeStance Health Group's net margin of -15.69%. The Pennant Group's return on equity of 13.42% beat LifeStance Health Group's return on equity.
Summary
The Pennant Group beats LifeStance Health Group on 13 of the 17 factors compared between the two stocks.
Get The Pennant Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PNTG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Pennant Group Competitors List
Related Companies and Tools
